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Abstract – The in vitro inhibitory effect of SR 27417, an antagonist of the platelet-activating factor
(PAF) receptor, on PAF-induced platelet aggregation was studied in blood collected from seven
healthy Friesien calves. Inhibitory effects of SR 27417 were determined at thirteen different con-
centrations (0.1 – 400 nM) by using the dose-response curves of PAF on calf platelet aggregation. In
the presence of SR 27417, the maximal slopes of aggregation (%/min) induced by low and high
concentrations of PAF were significantly different from the control values obtained without an antag-
onist at p £ 0.05 and p £ 0.01 respectively. In vitro PAF-induced calf platelet aggregation was dose-
dependently inhibited by SR 27417. The drug inhibited PAF-induced platelet aggregation in a com-
petitive reversible manner (pA2 = 10.46 – 2.36 mol.L–1). In conclusion, the results of our study
showed that addition of SR 27417 to bovine platelet in vitro inhibits PAF-induced platelet aggrega-
tion.
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Résumé – Effet inhibiteur in vitro du SR 27417, un puissant antagoniste du récepteur du fac-
teur d’activation plaquettaire sur l’agrégation des plaquettes induite par le PAF chez le bovin.
L’effet inhibiteur in vitro du SR 27417, un antagoniste du récepteur du facteur d’activation pla-
quettaire (PAF) induite par le PAF sur l’agrégation plaquettaire a été étudiée dans le sang prélevé des
sept veaux sains de race Frisonne. L’effet inhibiteur du SR 27417 a été déterminé avec treize concen-
trations différentes (0,1 – 400 nM) en utilisant les courbes dose-effet du PAF sur l’agrégation
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1. INTRODUCTION
It is recognised that the platelet-activating
factor (PAF), an ether phospholipid, is con-
sidered as one of the most potent inducers of
platelet aggregation, inducing shape change
and degranulation of platelets in calves [2, 3,
8] and in other animal species [11, 15, 17,
36]. As predicted, bovine platelets are very
sensitive to PAF when this mediator is added
in platelet-rich plasma [2–5]. Recently, a
report showed that the morphological ultra-
structure of blood platelets in bovines are
modified following PAF infusion [4]. PAF
serves as an autacoid in a wide range of
physiological and pathological processes
[11]. The key determinant controlling
whether it serves a haemostatic or detri-
mental function may be the circumstances
under which PAF or related compounds are
generated [1, 11, 16, 18, 19, 32, 36]. In addi-
tion, Chignard et al. [15] defined a possible
role for PAF in bovine inflammatory dis-
eases. Moreover, PAF is believed to be
involved in acute allergic responses, asthma,
anaphylactic and septic shock [11, 18, 21,
29]. Since this mediator may also play an
important role in respiratory diseases in cat-
tle and in various other species [1, 24, 25,
27, 38], the development of specific platelet-
activating factor receptor antagonists which
can inhibit PAF receptor binding is there-
fore essential in order to elucidate the patho-
physiological roles of PAF and to develop
new drugs active in various situations where
PAF is believed to be involved.
The determination of the inhibition of
PAF-induced platelet aggregation has been
proposed as a biological standardization
method for commercially available drugs
[2–4, 8, 10, 13, 19, 30]. Based on this model,
a large number of PAF antagonists has been
identified in the past few years. These sub-
stances include structural analogues of PAF
and compounds chemically unrelated to
PAF [2, 10, 12, 21, 31, 35, 37]. The structure
of SR 27417 (fumarate salt) N-(2-dimethy-
lamino ethyl)-N-(3-pyridinylmethyl)
[4-(2,4,6-triisopropylphenyl)-thiazol-2-yl]
amine [6, 18, 22–24], belonging to a newly
developed series of PAF antagonists, has
been described as being one of the most
potent PAF receptor antagonist known to
date when compared with other PAF antag-
onists [22]. These data were obtained on
human, guinea pig, rat and rabbit platelets
[23, 24]. However, no such data were
obtained for cattle.
Therefore, the purpose of this study was
to assess in vitro influence of SR 27417 on
the dose-response curve of PAF on platelet
aggregation in normal calf blood.




as controlled by HPLC) was obtained from
Bachem Feinchemikalien AG (Bubendorf,
Switzerland) and stored as stock solution
(1 mg.mL–1) in Ethanol at –20 °C. Serial
dilutions were prepared in phosphat buffered
saline (PBS, PO4 buffer 0.05 mol.L–1 –
NaCl 0.85%) containing 0.25% bovine
plaquettaire des veaux. En présence du SR 27417, la pente d’agrégation maximale de la courbe
(%/min) induite par de faibles et fortes concentrations du PAF ont été significativement différentes
des valeurs de base (p £ 0.05 et p £ 0.01 respectivement). L’agrégation des plaquettes induites par le
PAF a été inhibée in vitro par le SR 27417 d’une manière dépendante de la dose. Le médicament a
inhibé in vitro l’agrégation induite par le PAF des plaquettes chez le bovin de façon compétitive et
réversible (pA2 = 10.46 – 2.36 mol.L–1). En conclusion, les résultats de notre étude montrent in
vitro que l’addition du SR 27417 aux plaquettes chez le bovin inhibe l’agrégation plaquettaire induite
par le PAF.
bovin / plaquette / agrégation plaquettaire / facteur d’activation plaquettaire (PAF) / SR 27417
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serum albumin (BSA) for platelet studies.
The SR 27417 (fumarate salt) N-(2-dimethy-
lamino ethyl)-N-(3-pyridinylmethyl)
[4-(2,4,6-triisopropylphenyl)-thiazol-2-yl]
amine was supplied by Sanofi Recherche
(S.R.) (Toulouse, France). SR 27417 was
dissolved on the day of the experiment in
saline (NaCl 0.9% solution). The diluted
solutions of PAF and SR 27417 were dis-
carded each day.
2.2. Animals
Seven healthy Friesien calves, weighing
100 – 10 kg, were used as experimental ani-
mals for the collection of fresh blood.
2.3. Calf platelet aggregation
Blood samples (50 mL) were collected
by puncture of the jugular vein in 5 mL
“vacutainer” tubes (containing 0.5 mL of
3.8% trisodium citrate). The aggregation
was assessed following the BORN method
[9]. Platelet-rich plasma (PRP) and platelet-
poor plasma (PPP) were prepared as previ-
ously described [2]. PRP was prepared from
citrated venous blood by centrifugation at
270 · g for 20 min at 100 °C and then by
collecting the upper two-thirds of the plasma
with a plastic pipette. PPP was obtained
by recentrifuging the remaining blood at
4 350 · g for 15 min at 10 °C. The final sus-
pension of PRP was adjusted to contain
300 000 platelets per m L with homologous
PPP. PRP was incubated in aliquots of
1 mL at 37 °C for 1 min (12 aliquots per
animal). After 1 min, 10 m L graded PAF
solution (10–5 _ 10–10 mol× L–1) were added
and the aggregation response was recorded
for each concentration with a dual channel
chronologue aggregometer with interface
and software (Corp.-model 490-aggro/link
software for Windows). 
Inhibitory effects of SR 27417 were
determined by using the dose-response
curves of PAF on platelet aggregation. One
minute before PAF, 10 m L of SR 27417 at
thirteen different concentrations (0.1, 0.5,
1, 2, 5, 10, 15, 20, 50, 100, 200, 300,
400 nM) were added in the cuvette. Results
were expressed as the maximal slope of
aggregation (%.min–1) [2]. The agro/link
software automatically calculates the max-
imum slope (in percent of scale per minute)
of the aggregation curve.
2.4. Calculation of the pA2 value 
related to SR 27417
The pA2 is defined as the negative loga-
rithm to base 10 of the molar concentration
of an antagonistic drug which requires the
doubling (= pA2) of the concentration of an
agonistic drug in order to produce the same
effect. In the present work, the pA2 value
related to SR 27417 was calculated taking
into account the change in the concentra-
tion of PAF inducing a 50% effect of the
maximum effect (ED50) measured for each
test from the dose-response curve. The pA2
value for SR 27417 using the calves’
platelets in PRP was determined from a
Schild plot [26, 34] and analysed as
described in [2].
2.5. Statistical analysis
The mean values – standard error of the
mean (SEM) at the various concentrations of
drug (SR 27417) were compared with con-
trol values by a nonparametric Wilcoxon
ranks-test. p-values £ 0.01 and £ 0.05 were
chosen to indicate a significant difference
[28].
3. RESULTS
The values of the maximal slope of
aggregation (%/min) obtained in the absence
(control) and in the presence of increasing
concentrations of SR 27417 for PAF-
induced aggregation of calf platelets in PRP
are given in Figure 1. 
As shown by Figure 1, in vitro and
Table I, PAF-induced calf platelet aggrega-
tion was dose-dependently inhibited by
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SR 27417 pretreatment. In the presence of
SR 27417, the maximal slope of aggrega-
tion induced by low and high concentra-
tions of PAF (for the seven calves) were
significantly different from the control val-
ues obtained without antagonist (at p £ 0.05
and p £ 0.01 respectively).
In the presence of all the different con-
centrations of SR 27417, the concentration-
response curves of PAF on platelet aggre-
gation were inhibited. The parallel shifts
of the dose-response curve to the right
indicated competitive antagonism. The pA2
value for SR 27417 measured over a range
of SR 27417 concentrations of 0.1- 10 nM,
and taking into account mean values was
10.46 – 2.36 mol.L–1. The mean Schild
regression was linear and had a slope not
significantly different (p < 0.05) from unity
(0.35 – 0.09).
4. DISCUSSION
Our results showed for the first time that
SR 27417 inhibits PAF-induced platelet
aggregation in an in vitro model using calf
blood.
The control values of maximal slope of
aggregation support the previous results
observed [2–4], showing that increasing con-
centrations of PAF can induce reversible and
irreversible platelet aggregation in calves.
The present study showed that SR 27417
dose-dependently inhibits bovine platelet
aggregation induced by both low and high
concentrations of PAF. The parallel shifts
of the dose-response curve to the right indi-
cated competitive antagonism. These results
were comparable with those obtained with
washed rabbit platelets [2, 21, 23], in spite of
the use of different methods for the pro-
cessing of platelets (washed or unwashed).
Evidence has been demonstrated that
PAF is intimately involved in the etiology of
a variety of disorders including septic shock,
anaphylaxis, thrombosis, hypotension, vaso-
constriction, increased pulmonary artery
pressure, increased pulmonary vascular
resistance, induction of pulmonary oedema,
Figure 1. Concentration response curves for PAF-induced aggregation of calve platelets in PRP in
the absence and in the presence of increasing concentrations of SR 27417. Values are Means – SEM
(n = 7) of the maximal slope of aggregation (%.min–1).
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asthma and allergy [1, 7, 11, 14, 16, 18, 24,
25, 27, 33, 37–39]. In addition, PAF infusion
induces moderate thrombocytopenia in
calves [4].
Therefore, the development of a specific
PAF receptor antagonist could offer a ratio-
nal and novel therapeutic approach for these
diseases. SR 27417 has an inhibitory effect
in vitro on the PAF induced aggregation of
rabbit and human platelets and on the oxida-
tive burst of guinea pig peritoneal macro-
phages [21, 23]. This potency was not only
expressed in vitro, but also by the ability of
SR 27417, in vivo, to inhibit PAF-induced
responses in mice and guinea pigs [6]. In
fact, this inhibition was noticeable by an
extremely long duration of activity. As
already reported for other PAF antagonists
in vivo models, SR 27417 was about
120 times more potent than WEB 2086 in
inhibiting PAF-induced oedema formation
in rabbit skin [22]. These results confirm
data from other sources [20], showing that
SR 27417 is one of the most potent PAF
receptor antagonists.
In addition, when compared with the tri-
azolothienodiazepine WEB 2086, SR 27417
was 70 times more potent against PAF-
induced aggregation of rabbit and human
platelets, respectively [22]. The present
in vitro experiment, however, demonstrated
that SR 27417 (pA2 = 10.46) was 37 times
more potent in PAF-induced aggregation of
bovine platelets than WEB 2086 (pA2 =
7.61) [2]. Since the mean of SR 27417
Schild regression was linear and had a slope
not significantly different from unity, these
data satisfied the condition for competitive
antagonism. The SR 27417 has been shown
to be a highly potent, specific and compet-
itive PAF receptor antagonist by its
inhibitory results either in vitro or in vivo
[21, 22]. 
In conclusion, these results showed that
addition of SR 27417 to bovine platelets
in vitro very effectively inhibits PAF-
induced platelet aggregation in this species
and suggests that SR 27417 may be a useful
experimental drug with which to investi-
gate the role of PAF in several bovine dis-
eases.
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